DCIS Margins and Genomic Profiles—Refresh Not Rehash!

Дата публикации: 01-09-2026 00:00:00

Optimizing local control in ductal carcinoma in situ (DCIS) is important because half of local failures are invasive with an antecedent risk of death. Margin width and adjuvant therapy have been a focus of investigation for many years as modifiable factors impacting local failure. Six large prospective trials (including National Surgical Adjuvant Breast and Bowel Project [NSABP] B-35) have investigated the role of adjuvant radiation and/or endocrine therapy; however, none addressed margin width. Therefore, I commend Wapnir et al for analyzing the margin width data from the NSABP B-35 trial to fill a gap in evidence pertaining to the ever-vexing problem of defining adequate margins in DCIS. The authors found a marginal, albeit statistically significant, difference in 10-year cumulative unadjusted local failure rate for both 1-mm and 2-mm discriminant thresholds; as expected, in models adjusting for other clinical factors, margin width was not a significant predictor of local recurrence.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Lumpectomy Margins and Local Recurrence in DCIS	0	8.55	01-09-2026
2	Perioperative Toripalimab in Stage III Non–Small Cell Lung Cancer	0	14.35	01-09-2026
3	Augmented Reality Thoracic Surgery and the Patient Experience	0	9.4	01-09-2026
4	FLOT vs CROSS in Esophageal Adenocarcinoma	0	6.05	01-09-2026
5	Q&A: Combining diagnosis, staging, tumor localization and surgery into a minimally invasive procedure for lung cancer	0	6.9	02-09-2026
6	MAIBE for Patients With Locally Advanced Pancreatic Cancer	0	5.92	01-09-2026
7	FLOT-Induced vs CROSS-Induced Pathological Complete Response	0	8.96	01-09-2026
8	Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non–Small Cell Lung Cancer	0	6.4	01-09-2026
9	Tumor response to immunochemotherapy may spare some head and neck cancer patients radical surgery	0	7.22	10-09-2026
10	New study finds a blood test may detect recurring breast cancer faster than a scan	0	8.6	31-08-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5.93. Источник: archderm.jamanetwork.com.